The Life Sciences team advised MacroGenics on its exclusive collaboration and license agreement with Zai Lab to develop and commercialize Margetuximab, MGD013 and TRIDENT™ molecule in greater China. Under the terms of the agreement, MacroGenics will receive an upfront cash payment of $25 million and will be eligible to receive up to $140 million in potential development and regulatory-based milestone payments. In addition, Zai Lab would pay MacroGenics double-digit royalties on annual net sales of the assets, which may be subject to adjustment in specified circumstances.
Zai Lab will obtain regional development and commercialization rights for these three immuno-oncology (I-O) programs in mainland China, Hong Kong, Macau and Taiwan. Zai Lab will also lead clinical development in its territory by leveraging its regulatory and clinical development expertise and broad regional network of investigators. As part of the collaborative clinical development effort, Zai Lab and MacroGenics intend to initiate a global study using combination regimens containing margetuximab in order to maximize potential clinical benefit in gastric cancer, the fifth most common cancer in the world and the second most common in China.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains.
The Goodwin team was led by partners Kingsley Taft and Noelle Dubiansky.
For additional details on the agreement, please read the press release.